PLGA and PLA for Veterinary Long-Acting Injectable Drug Development: Regulatory and Formulation Considerations

Introduction:

PLGA and PLA are biodegradable polyester polymers that can be engineered into controlled-release depots — microspheres, nanoparticles, in-situ forming systems, or implants — that maintain drug exposure over an extended period while potentially reducing dosing frequency. Their value in veterinary medicine goes beyond biodegradability alone: the real development challenge is controlling how the polymer degrades, how the API is released, how reproducibly the formulation can be manufactured, and how that translates into predictable safety and effectiveness in the target species.

Veterinary treatment presents practical challenges that make PLGA in drug delivery especially attractive as a platform: cattle on pasture, farmed fish, or free-roaming companion animals cannot always be handled on a strict repeat-dosing schedule. Species differences add complexity — dogs, cats, cattle, pigs, horses, and poultry differ substantially in physiology, metabolism, and injection-site characteristics, and FDA identifies horses, dogs, cats, cattle, pigs, chickens, and turkeys as the seven major species covered by its animal-drug framework.

Development objectives for these systems typically include extending drug release after a single administration, reducing dosing frequency, maintaining therapeutic concentrations for a targeted duration, reducing peak-to-trough fluctuations, and designing species-specific dosing regimens — but longer release is not automatically better. The desired release period should be driven by the API’s pharmacology, therapeutic window, target species, and clinical indication.

Summary:

• PLGA and PLA veterinary long-acting injectables can provide controlled drug release and reduce dosing frequency, driven by polymer composition, molecular characteristics, and degradation behavior.
• Formulation development must control polymer selection, API–polymer compatibility, particle/depot characteristics, drug loading, injection performance, sterility, stability, and release kinetics.
• In the U.S., FDA CVM’s GFI #238 specifically addresses modified-release veterinary parenteral dosage forms — CMC, pharmacokinetics, in-vitro release testing, IVIVC/IVIVR, and specifications.
• In Europe, EMA’s guideline on the quality of modified-release veterinary dosage forms (effective February 17, 2023) covers parenteral products designed to modify the rate or timing of API release.
• For food-producing species, development must also address tissue residues, withdrawal periods, and residue analytical methods, alongside target-animal safety, effectiveness, and environmental impact.
• A science- and risk-based strategy — connecting CQAs, CMAs, and CPPs — is central to both formulation development and regulatory submission success.

1: PLGA vs. PLA: Which Polymer Fits Which Veterinary Application?

PLA generally degrades more slowly than PLGA, making it useful when a longer or differently controlled release profile is required, while PLGA’s adjustable lactic-acid-to-glycolic-acid ratio gives developers more formulation-level control over degradation and release timing. PLGA is a copolymer of lactic and glycolic acid units whose composition and molecular characteristics can be tuned to shift the degradation profile; PLA is based on lactic acid units alone and typically shows different — generally slower — degradation behavior.

The choice between PLA and PLGA should be based on product-specific performance requirements rather than an assumption that one polymer is universally superior — actual behavior depends on the specific polymer grade, API, manufacturing process, dosage form, and administration conditions. Sponsors sourcing polymer for these programs typically start from a documented Certificate of Analysis for pharmaceutical-grade PLGA to confirm the material meets the specification the formulation was developed against.

2: How Does Species Physiology Change Formulation Design?

Body temperature, injection-site tissue composition, and metabolic rate vary widely across target species, so a formulation validated in one animal cannot be assumed to perform identically in another. Cattle, swine, companion animals, and aquaculture species present distinct injection-site vascularity and local immune response patterns that influence both drug release and injection-site reaction risk.

Key species-specific formulation levers include:

• Injection site and depot geometry — subcutaneous depots in cattle versus intramuscular depots in companion animals change local drug exposure and clearance
• Particle or implant size — microsphere formulations suit smaller-volume companion animal dosing; larger implants suit herd-scale livestock treatment
• Ambient and body temperature range — outdoor livestock and aquaculture applications require a wider validated operating window than a climate-controlled clinic
• Local tissue reaction tolerance — food animals have stricter carcass-quality and injection-site lesion tolerances than companion animals, since injection-site blemishes affect meat value
• Protein or peptide-based APIs — biologic veterinary actives, such as growth hormone or other protein therapeutics, carry their own stability risks inside a polymer matrix; work like stabilizing a growth hormone protein API illustrates the kind of formulation-stability investigation needed when a protein API must survive polymer encapsulation and depot degradation intact

3: Formulation Considerations: Polymer Selection Through Drug Loading

Successful formulation development requires control of polymer properties, API–polymer compatibility, particle/depot characteristics, drug loading, release kinetics, injection properties, and product stability — and each of these should be established experimentally rather than assumed from supplier specifications.

Polymer selection is one of the earliest formulation decisions and should account for polymer composition, molecular weight and distribution, end-group chemistry, purity, residual monomers and solvents, crystallinity, glass-transition characteristics, and degradation profile. Guidance on PLGA long-acting injectable formulation approaches can help sponsors map these polymer attributes to a target release profile early in development.

API–polymer compatibility should be evaluated before finalizing the formulation, since chemical or physical interactions can affect potency, degradation, loading efficiency, and release. Relevant investigations include API assay and purity, related substances, thermal and solid-state behavior, polymer–API interactions, moisture sensitivity, and degradation products.

Particle size and morphology strongly affect performance in microsphere or particulate systems. Typical characterization includes particle-size distribution (D10, D50, D90), morphology, surface characteristics, porosity, and aggregation tendency — all of which must also be compatible with the intended syringe and needle for administration. The manufacturing route chosen to hit a target particle profile matters here too; a spray drying vs. solvent evaporation comparison is often the starting point when selecting a particle-formation process for a veterinary depot.

Drug loading and encapsulation efficiency are important CQAs because changes in either affect dose accuracy and release behavior:

• Drug loading (%) = Amount of encapsulated API ÷ Total microsphere mass × 100
• Encapsulation efficiency (%) = Actual drug encapsulated ÷ Theoretical drug used × 100

4: How Is Drug Release Evaluated for PLGA and PLA Veterinary Long-Acting Injectables?

Drug release should be evaluated using a scientifically justified in-vitro method capable of distinguishing meaningful formulation and manufacturing differences and, where possible, correlating in-vitro performance with in-vivo behavior. FDA CVM’s GFI #238 specifically discusses development of in-vitro drug-release methods for modified-release veterinary parenteral dosage forms, including clinically relevant release specifications and the potential role of an in-vitro/in-vivo correlation (IVIVC) or relationship (IVIVR).

A release program may examine initial burst release, early and sustained-release phases, total release, release duration, batch-to-batch variability, and release after stability storage. A simplified release profile typically moves through three phases:

1. Initial phase — drug near the surface releases relatively quickly
2. Diffusion-controlled phase — drug moves through the intact polymer matrix
3. Polymer-degradation phase — polymer erosion increasingly drives release

The exact mechanism varies with formulation composition and manufacturing conditions, which is why an IVIVC/IVIVR strategy matters: it connects polymer properties → formulation attributes → in-vitro release → pharmacokinetics → clinical performance, helping developers understand why apparently small formulation changes can produce meaningful shifts in animal exposure.

5: What Regulatory Pathways Govern PLGA/PLA Veterinary Injectables?

In the U.S., modified-release veterinary parenteral products are specifically addressed by FDA CVM guidance; in the EU, EMA’s dedicated modified-release veterinary dosage-form guideline covers the same product category; and VICH harmonized guidance aligns CMC, safety, and residue-testing expectations across major regions. Unlike human drug review, veterinary approval for food-producing species adds a residue chemistry and withdrawal-period dossier with no direct human-drug equivalent.

FDA describes five major technical areas in animal-drug development, all of which apply to a long-acting injectable program:

For food-producing animals, developers must additionally account for drug residues, edible tissues, withdrawal periods, and validated residue analytical methods. FDA explains that residue chemistry studies assess drug residues in edible tissues — meat, milk, eggs, or honey — depending on the species and product, and requires practicable analytical methods for identifying unsafe residues before approval. This is particularly important for long-acting formulations, since the polymer system is intentionally designed to extend drug exposure, which can also extend the residue depletion timeline if not carefully controlled.

6: What CMC and Analytical Data Do Regulators Expect?

Regulators expect CQAs to be established based on their potential impact on product quality, safety, efficacy, and performance — not a generic checklist applied to every formulation. Potential CQAs for a PLGA/PLA veterinary injectable include appearance, identification, assay, related substances, drug loading, encapsulation efficiency, particle-size distribution, morphology, residual solvents, water content, polymer molecular weight and composition, in-vitro release profile, sterility, bacterial endotoxins where applicable, and stability-indicating attributes.

A robust analytical strategy should characterize both the API and the polymeric delivery system:

• API characterization — HPLC/UPLC, LC-MS, GC where appropriate, UV/Vis, NMR where justified
• Polymer characterization — GPC/SEC for molecular weight, NMR for composition, DSC for thermal properties, TGA for decomposition behavior, FTIR for chemical identity
• Formulation characterization — laser diffraction or equivalent particle-size analysis, microscopy/SEM, HPLC assay and impurity profiling, residual-solvent GC, moisture analysis, and in-vitro release testing

An orthogonal analytical strategy is particularly valuable here, since no single technique fully describes the relationship between polymer degradation and drug release. This is the same cross-disciplinary skill set — polymer science, mass spectrometry, and impurity profiling combined — that underpins human PLGA depot characterization work such as PLGA inhalable microparticle development, and it transfers directly to veterinary programs.

7: Stability, Manufacturing Scale-Up, and Common Development Risks

Stability programs for PLGA/PLA systems must monitor more than conventional API degradation, because polymer molecular-weight reduction, increased local acidity from polymer breakdown, particle aggregation, and changing release kinetics can all shift over shelf life even when API assay remains within specification — making release testing itself an important stability attribute for long-acting systems.

Scale-up is a critical risk point: changes in mixing intensity, organic-to-aqueous phase ratio, emulsification conditions, temperature, solvent removal rate, drying, and sterilization strategy can alter the release profile even when the nominal formulation composition is unchanged. A useful development framework follows QTPP → CQAs → CMAs/CPPs → risk assessment → design space/control strategy → process validation, consistent with ICH Q8/Q9/Q10 principles. Experience scaling PLGA microsphere manufacturing from lab to commercial batch size is directly relevant to veterinary programs facing the same cost-per-dose and batch-consistency pressures as human depot products, and sourcing consistently characterized GMP-grade PLGA for clinical supply is a common early risk-mitigation step.

The most common development risks include:

• Excessive initial burst release or incomplete drug release
• Unexpectedly rapid polymer degradation or API degradation within the matrix
• Particle aggregation, poor syringeability, or needle blockage
• Injection-site tolerability issues (with added carcass-quality implications in food animals)
• Batch-to-batch release variability and residual solvent variability
• Stability-induced changes in release profile
• Weak IVIVC/IVIVR relationships that undermine the regulatory data package

8: How ResolveMass Can Support PLGA/PLA Veterinary Long-Acting Injectable Development

ResolveMass Laboratories Inc. supports analytical development and characterization activities that help developers understand API, impurity, formulation, and stability behavior throughout long-acting injectable development, structured around the specific development stage and scientific questions being investigated. Analytical support spans HPLC/UPLC method development, API assay and impurity profiling, LC-MS characterization, GC-based residual-solvent testing, stability-indicating analysis, forced-degradation studies, and polymer/formulation characterization built around an orthogonal analytical strategy.

For a long-acting veterinary formulation, the most useful analytical program is not a collection of individual tests — it establishes the relationships between material attributes, process conditions, release behavior, and stability that regulators expect to see connected in a CMC submission. ResolveMass operates an ISO 9001:2015-certified quality management system supporting these analytical development and characterization programs.

Conclusion:

PLGA and PLA veterinary long-acting injectables require an integrated approach combining polymer science, formulation development, analytical characterization, pharmacokinetics, manufacturing controls, stability, and veterinary-specific regulatory requirements. Their potential to provide extended, single-dose release makes them attractive platforms, but a predictable and reproducible product depends on tightly controlling both material and process variables. For U.S. programs, FDA CVM GFI #238 provides the core framework for modified-release veterinary parenterals; European programs should build against the EMA modified-release dosage-form guideline. Sponsors developing PLGA and PLA veterinary long-acting injectables benefit from bringing analytical characterization and regulatory strategy into the program from day one rather than layering it in at the end.

Frequently Asked Questions:

Reference

• Matschke C, Isele U, van Hoogevest P, Fahr A. Sustained-release injectables formed in situ and their potential use for veterinary products. Journal of Controlled Release. 2002 Dec 13;85(1-3):1-5.https://www.sciencedirect.com/science/article/pii/S0168365902002663
• Koppisetti H, Abdella S, Nakmode DD, Abid F, Afinjuomo F, Kim S, Song Y, Garg S. Unveiling the future: opportunities in long-acting injectable drug development for veterinary care. Pharmaceutics. 2025 May 8;17(5):626.https://www.mdpi.com/1999-4923/17/5/626
• Winzenburg G, Schmidt C, Fuchs S, Kissel T. Biodegradable polymers and their potential use in parenteral veterinary drug delivery systems. Advanced drug delivery reviews. 2004 Jun 23;56(10):1453-66.https://www.sciencedirect.com/science/article/pii/S0169409X04000742
• Martinez M, Rathbone M, Burgess D, Huynh M. In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting. Journal of Controlled Release. 2008 Jul 14;129(2):79-87.https://www.sciencedirect.com/science/article/pii/S0168365908001867
• Selmin F, Musazzi UM, Magri G, Rocco P, Cilurzo F, Minghetti P. Regulatory aspects and quality controls of polymer-based parenteral long-acting drug products: the challenge of approving copies. Drug Discovery Today. 2020 Feb 1;25(2):321-9.https://www.sciencedirect.com/science/article/pii/S1359644619304672
• Muddineti OS, Omri A. Current trends in PLGA based long-acting injectable products: The industry perspective. Expert opinion on drug delivery. 2022 May 4;19(5):559-76.https://www.tandfonline.com/doi/abs/10.1080/17425247.2022.2075845

About the Author

Priyal Darji